Febuxostat - Treatment for hyperuricemia and gout?

New England Journal of Medicine

Volumn 353, Issue 23, 2005, Pages 2505-2507

  Moreland, Larry W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOPURINOL; AZATHIOPRINE; COLCHICINE; CREATININE; FEBUXOSTAT; MERCAPTOPURINE; NAPROXEN; OXIPURINOL; PROBENECID; PURINE; THEOPHYLLINE; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; BONE MARROW SUPPRESSION; CREATININE CLEARANCE; DIETARY INTAKE; DRUG ABSORPTION; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; EOSINOPHILIA; GASTROINTESTINAL TOXICITY; GOUT; HEPATITIS; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; PRIORITY JOURNAL; PURINE METABOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; UREMIA; URIC ACID BLOOD LEVEL; URINARY EXCRETION; VASCULITIS;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; PROBENECID; THIAZOLES; URIC ACID; XANTHINE OXIDASE;

EID: 28944443551     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058247     Document Type: Editorial

References (14)

1. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5.
2. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103.
3. Becker MA, Jolly M. Metabolic bone and joint disease. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:2303-39.
4. Hahn PC, Edwards NL. Management of hyperuricemia. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:2341-55.
5. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
6. Terkeltaub RA. Gout. N Engl J Med 2003;349:1647-55.
7. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
8. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Current Opin Rheumatol 2005;17:319-24.
9. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.
10. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
11. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47.
12. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase, in subjects with renal impairment. Am J Ther 2005;12:22-34.
13. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
14. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43.